Savolitinib, TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets, Savolitinib, TAGRISSO 40 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets
SAVANNAH/D5084C0007
Phase 2 small_molecule active
Quick answer
Savolitinib, TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets, Savolitinib, TAGRISSO 40 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets for EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active